reports
PubMatic to Participate in Upcoming Financial Conferences
PubMatic to Participate in Upcoming Financial Conferences NO-HEADQUARTERS/REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced that members of its management team are scheduled to participate at the following upcoming financial conferences: Oppenheimer’s 28th Annual Technology, Internet & Communications Conference on Wednesday, August 13, 2025. Management will participate in a virtual webcasted fire-side chat at 11:35 a.m. ET / 8:35 a.m. PTRosen...
PubMatic Announces Second Quarter 2025 Financial Results
PubMatic Announces Second Quarter 2025 Financial Results Delivered revenue and adjusted EBITDA ahead of guidance; Revenue from omnichannel video, including CTV, grew 34% year-over-year and was 41% of total revenue; CTV revenue grew over 50% year-over-year; Supply Path Optimization represented 55%+ of total activity; and Repurchased 3.5 million shares in Q2 2025, representing 7% of fully diluted shares. NO-HEADQUARTERS/REDWOOD CITY, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain o...
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second generation kits in June NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its second quarter results: Fellow shareholders, We are closer than we have ever been to deli...
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Att...
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the followin...
IMDX World Transplant Congress Late-Breaking Data Potentially Sets New...
IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined scoreData show significantly improved positive predictive value (PPV) for graft rejection, which potentially broadens clinical utility for dd-cfDNA with fewer false positives, further reducing unnecessary invasive biopsies for patientsiMDx expects to evaluate combined score in ongoing FDA study (NCT07060716)iMDx will be exhibiting at Booth #324 at the Worl...
iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testin...
iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025 NASHVILLE, Tenn., July 28, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will host a virtual key opinion leader (KOL) event on Friday, August 15, 2025 at 4:00 PM ET featuring Anthony Langone, MD (Associate Professor of Medicine, Division of Nephrology and Hypertension, Vanderbilt University). To register, Dr. Langone, who serves as the national principal investigator (NPI) for iMDx’s ongoing kidney transplant...
PubMatic Launches AI-Powered Live Sports Marketplace with Real-Time Ga...
PubMatic Launches AI-Powered Live Sports Marketplace with Real-Time Game Moment Curation, FanServ Joins as Premier Partner Capitalizing on an Exponential Increase in Demand, the Marketplace delivers up-to-the-minute inventory access and curation capabilities REDWOOD CITY, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- PubMatic (Nasdaq: PUBM), the independent technology company delivering digital advertising's supply chain of the future, today launched an AI-powered Live Sports Marketplace that enables advertisers to target specific game moments across streaming platforms in real-time. This b...
PubMatic to Announce Second Quarter 2025 Financial Results on August 1...
PubMatic to Announce Second Quarter 2025 Financial Results on August 11, 2025 NO-HEADQUARTERS/REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced that it will release its financial results for the second quarter ended June 30, 2025 after market close on Monday, August 11, 2025. On that day, PubMatic will host a webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss the company’s financial results. Webcast Details What: PubMati...
iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection T...
iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patientsData was presented at the European Renal Association (ERA) 2025Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2Upcoming National Principal Investigator and Key Opinion Leader call planned NASHVILLE, Tenn., June 23, 20...
Barnwell Announces Third Adjournment of 2025 Annual Meeting Due to Ned...
Barnwell Announces Third Adjournment of 2025 Annual Meeting Due to Ned Sherwood’s Continued Refusal to Submit Votes Solicited from Shareholders HONOLULU, June 18, 2025 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) (“Barnwell” or the “Company”) today announced that its 2025 Annual Meeting of Shareholders, which reconvened yesterday, has been adjourned to Wednesday, September 3, 2025. Shareholders of record at the close of business on July 21, 2025 are eligible to vote at the adjourned 2025 Annual Meeting. Shareholders are encouraged to vote on the WHITE proxy card FOR...
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Mo...
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology careiMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globallyExhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025 NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has anno...
Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology
Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology New price of $2,753 for the GraftAssureCore™ assay increases total addressable market size and margin opportunityBrings pricing in line with existing competitive technologyExpands market appeal for prospective FDA-cleared kitted product at transplant centers IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test (LDT), GraftAssureCore. The new reimbursement rate strengthens the co...
PubMatic to Participate in Upcoming Financial Conferences
PubMatic to Participate in Upcoming Financial Conferences NO-HEADQUARTERS/REDWOOD CITY, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced that members of its management team are scheduled to participate and host investor meetings at the following upcoming financial conferences: Jefferies Public Technology Conference on Wednesday May 28, 2025. Management will host one-on-one meetings. Evercore ISI “Nothing But Net” Internet Investors Summit on Wednesday May ...
Barnwell Industries, Inc. Reports Results for its Second Quarter Ended...
Barnwell Industries, Inc. Reports Results for its Second Quarter Ended March 31, 2025 HONOLULU, May 15, 2025 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) today reported financial results for its second quarter ended March 31, 2025. For the quarter, the Company had revenue from continuing operations of $3,569,000 and a net loss from continuing operations of $1,538,000 or $0.15 per share. In the prior year quarter ended March 31, 2024, the Company reported quarterly revenue from continuing operations of $4,678,000 and a net loss from continuing operations of $1,306,000...
Oncocyte Reports Q1 2025 Results and Business Progress
Oncocyte Reports Q1 2025 Results and Business Progress Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are now using our GraftAssure research-use-only kitsTo reflect our larger market opportunity, we plan to rename the company in Q2 IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first quarter ...
PubMatic Announces First Quarter 2025 Financial Results; Board of Dire...
PubMatic Announces First Quarter 2025 Financial Results; Board of Directors Authorizes $100M Expansion of Share Repurchase Program Delivered revenue and adjusted EBITDA ahead of guidance; Revenue from omnichannel video, including CTV, grew 20% and was 40% of total revenue; CTV revenue grew over 50% year-over-year; and Supply Path Optimization represented a record 55%+ of total activity NO-HEADQUARTERS/REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today...
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
Oncocyte to Release First Quarter 2025 Results on May 12, 2025 IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: . An archived replay will be available after the c...
PubMatic Unveils AI-Powered Media Buying Platform
PubMatic Unveils AI-Powered Media Buying Platform Buy-Side Technology Enables Transparent Media Buying Across Full Open Internet Inventory NO-HEADQUARTERS/REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- PubMatic, a leader in digital advertising technology, today announced the launch of its upgraded solution suite for buyers, powered by generative AI. PubMatic’s buyer platform streamlines every stage of the media buying process – from audience and inventory discovery and forecasting to curation, activation, and performance optimization. It is the only solution with direct access t...
Oncocyte Provides Positive Update on Clinical Trial Progress
Oncocyte Provides Positive Update on Clinical Trial Progress Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its...
Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity
Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity Transplantation Direct publication uses assay to identify rejection in patients up to 13 years post-transplant Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in BerlinSupports market expansion for testing of high-risk patient populationNew findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced the publicatio...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.